Back to Browse Journals » Clinical Epidemiology » Volume 2

Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer

Authors Paul J Fitzgerald

Published Date December 2009 Volume 2010:2 Pages 1—3

DOI http://dx.doi.org/10.2147/CLEP.S8903

Published 24 December 2009

Paul J Fitzgerald

The Zanvyl Krieger Mind/Brain Institute, Solomon H. Snyder, Department of Neuroscience, Johns Hopkins University, Baltimore, MD, USA

Abstract: Recently, I put forth the hypothesis that the signaling molecule, norepinephrine (NE), is an etiological factor in a number of types of cancer. In this brief commentary, I summarize evidence that NE plays a role in cancer and describe details involved in testing the hypothesis in humans through epidemiological investigation of existing medical records of persons who have taken pharmaceutical drugs that affect NE. If NE plays an etiological role in cancers of a number of organs, then taking a single pharmaceutical drug (such as clonidine, prazosin, or propranolol) that weakens NE signaling systemically, may simultaneously prevent or treat many different types of cancer, and this may represent a breakthrough in pharmaceutical prevention and possibly treatment of cancer.

Keywords: norepinephrine, acetylcholine, cancer, clonidine, prazosin, propranolol

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint

Fitzgerald PJ

Clinical Epidemiology 2012, 4:151-156

Published Date: 29 June 2012

Readers of this article also read:

Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint

Fitzgerald PJ

Clinical Epidemiology 2012, 4:151-156

Published Date: 29 June 2012

Usefulness of serum mass spectrometry to identify women diagnosed with higher grades of cervical intraepithelial neoplasia may differ by race

Matthews R, Azuero A, Asmellash S, Brewster E, Partridge EE, Piyathilake CJ

International Journal of Women's Health 2011, 3:185-192

Published Date: 12 July 2011

Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt

Guan P, Lu Y, Qi J, Niu M, Lian R, Hu F, Wu W

International Journal of Nanomedicine 2011, 6:965-974

Published Date: 4 May 2011

Epigenomics in cancer management

Fabricio F Costa

Cancer Management and Research 2010, 2:255-265

Published Date: 27 October 2010

Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue

Thomas P Ahern, Mariann Christensen, Deirdre P Cronin-Fenton, et al

Clinical Epidemiology 2010, 2:241-246

Published Date: 22 October 2010

Hepatitis C virus infection and risk of cancer: a population-based cohort study

Lars Haukali Omland, Dora Körmendiné Farkas, Peter Jepsen, et al

Clinical Epidemiology 2010, 2:179-186

Published Date: 24 June 2010

Health literacy and health seeking behavior among older men in a middle-income nation

Paul A Bourne, Chloe Morris, Christopher AD Charles, et al

Patient Related Outcome Measures 2010, 1:39-49

Published Date: 26 May 2010

Tenofovir-associated bone density loss

Iwen F Grigsby, Lan Pham, Louis M Mansky, et al

Therapeutics and Clinical Risk Management 2010, 6:41-47

Published Date: 24 December 2009